Responses
Clinical and epidemiological research
Extended report
Difference in the risk of serious infections in patients with rheumatoid arthritis treated with adalimumab, infliximab and etanercept: results from the Dutch Rheumatoid Arthritis Monitoring (DREAM) registry
Compose a Response to This Article
Other responses
No responses have been published for this article.